Stifel Nicolaus analyst Annabel Samimy has reiterated their bullish stance on JAZZ stock, giving a Buy rating today.
Annabel Samimy’s rating is based on Jazz Pharmaceuticals’ strategic acquisition of Chimerix, which is expected to significantly bolster its oncology portfolio. The acquisition includes dordaviprone, a promising late-stage asset for treating H3 K27M-mutant diffuse glioma, a rare and aggressive form of brain cancer. This move aligns with Jazz’s focus on oncology and leverages its existing pediatric presence, potentially enhancing its commercial success.
The financial terms of the acquisition are favorable, with the transaction fully funded through Jazz’s existing cash reserves. Additionally, dordaviprone has shown impressive clinical efficacy and safety, receiving multiple designations from the FDA, including Rare Pediatric Disease and Fast Track. If approved, it could become a standard-of-care treatment, providing a new revenue stream and further solidifying Jazz’s position in the oncology market. These factors collectively support Samimy’s Buy rating for Jazz Pharmaceuticals.
In another report released today, Needham also maintained a Buy rating on the stock with a $210.00 price target.